Literature DB >> 1672808

Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease.

N W Kowall1, M F Beal.   

Abstract

Although formation of neurofibrillary tangles is a major pathological feature of Alzheimer's disease (AD), the neurotransmitter content of neurofibrillary tangle-bearing neurons has not been well characterized. We studied the hippocampus of 6 patients with pathologically verified AD and 6 control subjects using a monoclonal antibody to glutamyl-glutamate and polyclonal antisera against glutaminase and taurine. In normal hippocampus, glutamate and glutaminase stained pyramidal neurons in the cornu ammonis (CA) fields and the subiculum, as well as the dentate granule cells. Fiber staining was better seen with glutamate antisera, which in AD specimens showed reduced numbers of glutamate-immunoreactive fibers in the molecular layer of the dentate gyrus. In AD specimens, glutamate- and glutaminase-immunoreactive pyramidal neurons in the hippocampal CA fields were decreased in number and remaining neurons showed irregular shortened and disorganized dendritic fields. Taurine immunoreactivity was localized to a subset of hippocampal pyramidal neurons, which showed similar degenerative changes in AD specimens. Glutamate-, glutaminase-, and taurine-stained neurons were found to contain neurofibrillary tangles using either double immunofluorescence with tau antisera, double immunoperoxidase stains, or silver and thioflavine S counterstains. These studies show that two distinct neurochemically defined populations of pyramidal neurons in allocortex frequently show degenerative changes and develop neurofibrillary tangles in AD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672808     DOI: 10.1002/ana.410290208

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 2.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

Authors:  Timothy J Revett; Glen B Baker; Jack Jhamandas; Satyabrata Kar
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

3.  Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses?

Authors:  R F Squires; A Lajtha; E Saederup; M Palkovits
Journal:  Neurochem Res       Date:  1993-02       Impact factor: 3.996

Review 4.  The glutamatergic system and Alzheimer's disease: therapeutic implications.

Authors:  D Allan Butterfield; Chava B Pocernich
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Phosphorylated tau interactome in the human Alzheimer's disease brain.

Authors:  Eleanor Drummond; Geoffrey Pires; Claire MacMurray; Manor Askenazi; Shruti Nayak; Marie Bourdon; Jiri Safar; Beatrix Ueberheide; Thomas Wisniewski
Journal:  Brain       Date:  2020-09-01       Impact factor: 13.501

6.  Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways.

Authors:  Jennifer Fazzari; Katja Linher-Melville; Gurmit Singh
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  New Functions of APC/C Ubiquitin Ligase in the Nervous System and Its Role in Alzheimer's Disease.

Authors:  Tanja Fuchsberger; Ana Lloret; Jose Viña
Journal:  Int J Mol Sci       Date:  2017-05-14       Impact factor: 5.923

Review 8.  Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors.

Authors:  Sayad Kocahan; Zumrut Doğan
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-02-28       Impact factor: 2.582

9.  Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice.

Authors:  Kristen R Hollinger; Xiaolei Zhu; Elizabeth S Khoury; Ajit G Thomas; Kevin Liaw; Carolyn Tallon; Ying Wu; Eva Prchalova; Atsushi Kamiya; Camilo Rojas; Sujatha Kannan; Barbara S Slusher
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.160

10.  Aβ Induces Excitotoxicity Mediated by APC/C-Cdh1 Depletion That Can Be Prevented by Glutaminase Inhibition Promoting Neuronal Survival.

Authors:  T Fuchsberger; S Martínez-Bellver; E Giraldo; V Teruel-Martí; A Lloret; J Viña
Journal:  Sci Rep       Date:  2016-08-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.